Evidence map›Paper›PMID 42352417›Full record

ArticleCancers2026

Emerging Perspectives on Adverse Childhood Experiences and Brain Cancer Immunotherapy.

John W Figg, Julian Mark, Caretia J Washington, Anna Fusco, Maegan A Cremer, Scott A Cohen, Stephan Quintin, Deidre B Pereira, Ashley P Ghiaseddin

Abstract readComment
In one paragraph

Article in Cancers, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors.

John W FiggPreston A. Wells Jr. Center for Brain Tumor Therapy, Lillian S. Wells Department of Neurosurgery, University of Florida, Gainesville, FL 32611, USA.ORCID 0000-0002-9869-1094
Julian MarkMD/PhD Program, College of Medicine, University of Florida, Gainesville, FL 32610, USA.ORCID 0000-0003-4152-7725
Caretia J WashingtonMD/PhD Program, College of Medicine, University of Florida, Gainesville, FL 32610, USA.ORCID 0000-0002-1205-5848
Anna FuscoMD/PhD Program, College of Medicine, University of Florida, Gainesville, FL 32610, USA.
Maegan A CremerJ. Crayton Pruitt Family Department of Biomedical Engineering, University of Florida, Gainesville, FL 32611, USA.ORCID 0000-0001-9420-4802
Scott A CohenMD/PhD Program, College of Medicine, University of Florida, Gainesville, FL 32610, USA.ORCID 0000-0002-8758-180X
Stephan QuintinDepartment of Neuroscience, College of Medicine, University of Florida, Gainesville, FL 32610, USA.
Deidre B PereiraDepartment of Clinical and Health Psychology, University of Florida, Gainesville, FL 32611, USA.ORCID 0000-0002-9881-7670
Ashley P GhiaseddinPreston A. Wells Jr. Center for Brain Tumor Therapy, Lillian S. Wells Department of Neurosurgery, University of Florida, Gainesville, FL 32611, USA.ORCID 0000-0001-5599-4610

Funding

NCI NIH HHS 1F30CA298656-01A1
6 · The paper itself

Abstract

Adverse childhood events (ACEs) represent a major public health burden in the United States, as exposure to ACEs increases the risk of mental health disorders, cardiovascular disease, obesity, and cancer and can greatly affect quality of life. Although the effects of ACEs on physiology are complex, significant evidence suggests that ACEs may affect the immune system later in life. As the field of immunotherapy gains prominence in cancer treatment, it becomes imperative to explore how ACEs may impact cancer immunotherapy. Brain cancer, especially glioblastoma multiforme (GBM), has a very poor prognosis and remains a challenging disease to treat. Immunotherapy approaches are being actively investigated. To address this, we aim to raise awareness of the potential connection between ACEs, brain cancer, and cancer immunotherapy. Through a review of the current biomedical literature, we synthesized current findings into a commentary on how early-life adversity may influence the immune response within the central nervous system. It is the intention of this commentary to generate hypothesis-driven research within the nascent and emerging field of neuro-psycho-immunology in neuro-oncology. Given that the relationship between ACEs and brain cancer immunotherapy remains vastly understudied, this commentary has significant potential to generate insightful discussions among clinicians and scientists to guide further clinical and basic research towards anticipating which patients stand to receive the most benefit from immunotherapy.

Indexed as

adverse childhood experiences/eventsbrain cancerimmunotherapyneuroimmune

Identifiers

PMID42352417
PMCPMC13297074

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.